Caris Life Sciences (CAI) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $7.24B and a free-cash-flow yield of 1.6%. Over the most recent reported fiscal year, revenue grew 97.0%. Nama's AI scorecard rates it Buy, 7.1 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Buy · 7.1/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Middle · +10.1% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-55.0%
How far the last close sits under the highest price of the past five years.
Market cap
$7.24B
Trailing P/E
—
Price / book
12.1
Price / sales
7.2
FCF yield
1.6%
Dividend yield
—
Gross margin
69.7%
Operating margin
15.5%
Net margin
10.6%
Revenue growth (YoY)
+97.0%
Revenue growth (3-yr annual)
+46.5%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
CAI earnings
Beat the EPS estimate in 2 of 3 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q4 2025
Feb 26, 2026
$0.28
$0.10
+180.0%
$292.89M
Q3 2025
Nov 5, 2025
$0.08
-$0.14
+157.1%
$216.83M
Q2 2025
Aug 12, 2025
-$1.11
-$0.22
-404.6%
$181.40M
CAI analyst price target
Median target $35.00 from 13 analysts, ranging $22.00 – $38.00.
Nama's AI scorecard currently rates Caris Life Sciences Buy (7.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the CAI price target?
The median analyst price target from 13 analysts is $35.00, with a range of $22.00 – $38.00.
Is CAI Shariah compliant?
Nama's AAOIFI-style screen reads Caris Life Sciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.